Find actively recruiting immunotherapy clinical trials in the UK. Discover how checkpoint inhibitors, CAR-T, and cancer vaccines are transforming treatment across oncology and autoimmune diseases.
Free to use — Live data from ClinicalTrials.gov — Updated hourly
Immunotherapy harnesses your body's immune system to fight disease. Unlike chemotherapy which directly attacks cells, immunotherapy trains, boosts, or redirects immune cells to recognise and destroy cancer or modulate autoimmune responses.
Immunotherapy works through several mechanisms: checkpoint inhibitors (pembrolizumab, nivolumab) remove the "brakes" on immune cells so they can attack cancer; monoclonal antibodies target specific proteins on cancer cells; cancer vaccines train the immune system to recognise tumour antigens; and adoptive cell therapy engineers your own T-cells to fight cancer.
Actively recruiting studies in the United Kingdom
Loading trials from ClinicalTrials.gov...
Chemotherapy directly kills rapidly dividing cells (including healthy ones), causing side effects like hair loss and nausea. Immunotherapy works by activating your immune system to recognise and attack cancer cells specifically, which often results in different side effects and can produce longer-lasting responses.
Many immunotherapies are now approved for NHS use, including pembrolizumab for lung cancer and melanoma, nivolumab for several cancers, and atezolizumab. However, access depends on NICE approval for your specific cancer type and stage. Clinical trials provide access to newer immunotherapies before they are widely available.
Immunotherapy can cause immune-related side effects as your activated immune system may attack healthy tissue. Common effects include fatigue, skin rash, and inflammation of the lungs, liver, intestines, or thyroid. Most are manageable with prompt treatment. Your trial team will monitor you closely.
Immunotherapy is used across multiple conditions. Select your condition for targeted results.
How does immunotherapy compare with other cancer treatments?